$199.00
In Stock
The antitumor drug Lanvis is prescribed for leukemia, mainly acute myeloblastic leukemia and acute lymphoblastic leukemia.
Disrupts DNA synthesis, blocks the mitotic process in the tumor cell. Has relative selectivity for bone marrow cells.
Used primarily in combination therapy for acute and chronic leukemia. The effectiveness of use depends on age and previous chemotherapy. Particularly effective in combination with cytarabine and prednisolone for acute and chronic myelogenous leukemia. Can also be used in combination with antitumor antibiotics.
Being an antimetabolite of the purine analog group, it has S-phase specificity; in the human body, thioguanine is quickly metabolized into active intracellular derivatives, the leading one of which is 6-thioguanylic acid. This acid is capable of inhibiting enzymes involved in the synthesis and utilization of purine nucleotides. After conversion into di- and triphosphate derivatives, the acid is incorporated into the resulting RNA and DNA chains in the form of “fictitious” phosphodiester bridges, thereby disrupting their synthesis. Data on the correlation of resistance of experimental tumors in animals to the action of thioguanine with the loss of enzyme activity indicate in favor of this mechanism, which converts thioguanine into thioguanylic acid. Another mechanism of resistance to the effects of thioguanine may be an increase in the catabolism of thioguanylic acid by non-specific phosphatases. Inhibits hematopoiesis.
Active ingredient: thioguanine
Prescription drug.
A drug called Thioguanin from Aspen is delivered from Germany
